Boyar Asset Management takes a business person’s approach to analyzing companies we invest in. For us to purchase common shares of a company for our clients, that enterprise must be intrinsically undervalued and have a sustainable business model. Simply put, we will not invest in companies that we feel are “fads.”
We also avoid purchasing shares in companies heavily reliant on technology that can quickly become obsolete. In addition, we do not invest in biotechnology companies, as it takes specialized expertise to correctly analyze those firms. Moreover, biotech companies often have binary outcomes in terms of investment success, which does not fit our margin-of-safety approach to investing.